Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study
CONCLUSION: In terms of the quantity of T100 articles, researchers, and organizations, the US is the predominant country. The most T100 papers were published in the special journal Clinical Infectious Diseases. The most academic focus remain the remedies for postherpetic neuralgia and vaccine development for individualized groups.PMID:37273270 | PMC:PMC10237222 | DOI:10.2147/JPR.S409616
Source: Herpes - June 5, 2023 Category: Infectious Diseases Authors: Ning Gao Meng Li Weiming Wang Lei Wang Zhen Liu Yufeng Guo Source Type: research

Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation. Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/ Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred year...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

What Do Hospitalists Need to Know About Monkeypox?
What is monkeypox? Monkeypox is a rare infection caused by the monkeypox virus. Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus.1 It was first isolated in 1958 and identified as causing human disease in 1970. This pathogen was endemic in central and western African countries up until recently. Between 2018 to May 2022, about nine cases of monkeypox were confirmed in a few non-endemic countries.2 There are two strains of monkeypox: West African monkeypox ...
Source: The Hospitalist - June 24, 2022 Category: Hospital Management Authors: Daniel Hickman Tags: Clinical Guidelines Diagnostic Emerging Infections Infectious Diseases Source Type: research

Shingles: What triggers this painful, burning rash?
If you’re like 95% of American adults, you had chickenpox as a kid. Before the United States started its widespread vaccination program in 1995, there were roughly four million cases of chickenpox every year. So, most people suffered through an infection with this highly contagious virus and its itchy, whole-body rash. But unlike many childhood viruses, the varicella-zoster virus that causes chickenpox doesn’t clear from the body when the illness ends. Instead it hangs around, taking up residence and lying dormant in the nerves, sometimes for decades, with the immune system holding it in check. In some people, it lives...
Source: Harvard Health Blog - December 14, 2020 Category: Consumer Health News Authors: Kelly Bilodeau Tags: Health Healthy Aging Skin and Hair Care Vaccines Source Type: blogs

Postherpetic Neuralgia: Current Evidence on the Topical Film-Forming Spray with Bupivacaine Hydrochloride and a Review of Available Treatment Strategies
AbstractPurpose of ReviewThis is a comprehensive review of the literature about the use of bupivacaine hydrochloride for the treatment of post-herpetic neuralgia (PHN). It briefly reviews the background, biology, diagnosis and conventional treatment for PHN, and then introduces and compares the recent evidence for the use of topical bupivacaine.Recent FindingsPHN is defined by pain lasting 90  days or more after the initial presentation of herpes zoster (“Shingles”, HZ) rash and is the most common complication of this disease. A product of re-activation of the Varicella-Zoster virus (VZV), HZ is diagnosed more than 1 ...
Source: Advances in Therapy - April 14, 2020 Category: Drugs & Pharmacology Source Type: research

Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition
Our objective was to develop comprehensive national estimates of the total burden of herpes zoster (HZ) among U.S. adults, including direct (ie, medical costs) and indirect (ie, productivity losses) costs, as well as its psychosocial impact (ie, quality of life losses). Using a patient-level microsimulation model, we projected health and economic outcomes among U.S. adults aged 18 years and older using a 10-year time horizon. We conducted a comprehensive systematic literature review to generate parameter values and conducted simulation modeling to generate our outcomes, including numbers of cases of uncomplicated HZ, posth...
Source: Pain - January 23, 2020 Category: Anesthesiology Tags: Research Paper Source Type: research

Immunogenicity, Safety, and Tolerability of Live Attenuated VaricellaZoster Virus Vaccine (ZOSTAVAX ™) in Healthy Adults in India.
Conclusions: In healthy Indians ≥50 years, ZOSTAVAX was well tolerated and resulted in expected VZV-specific antibody titer levels at 6 weeks post-vaccination. PMID: 31325263 [PubMed - in process]
Source: Journal of the Association of Physicians of India - July 22, 2019 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Neurological and Ophthalmological Manifestations of Varicella Zoster Virus
Conclusions: HZ produces a spectrum of potentially blinding and life-threatening complications that adversely affect quality of life and increase health care costs. Individuals at risk for HZ, such as the elderly and immunocompromised, should be encouraged to receive the highly effective VZV vaccine to prevent HZ and its complications.
Source: Journal of Neuro-Ophthalmology - May 21, 2019 Category: Opthalmology Tags: State-of-the-Art Review Source Type: research

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Abstract Recombinant zoster vaccine (RZV; Shingrix), an adjuvanted glycoprotein vaccine, was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices for adults aged ≥50 years in October 2017 (1). The previously licensed live-attenuated zoster vaccine (ZVL; Zostavax) is recommended for adults aged ≥60 years. RZV is administered intramuscularly as a 2-dose series, with an interval of 2-6 months between doses. In prelicensure clinical trials, 85% of 6,773 vaccinated study participants reported local or systemic reactions after receiving RZV, with appr...
Source: MMWR Morb Mortal Wkl... - February 1, 2019 Category: Epidemiology Authors: Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies.
Abstract Population aging is a worldwide phenomenon with significant and manifold impacts on society. Advanced age correlates with the onset of frailty. In this vulnerable state, the immune response is weakened and a higher susceptibility to infectious diseases is observed. The present narrative review aims to cover the topic of herpes zoster (HZ) and its complications in frail populations. The lifetime risk of developing HZ is estimated at about 20-30%, and the risk increases with age. In older people, HZ can lead to the inability to recover the lifestyle, the interests, and the level of activity that existed bef...
Source: Aging Clinical and Experimental Research - May 2, 2018 Category: Geriatrics Authors: Zorzoli E, Pica F, Masetti G, Franco E, Volpi A, Gabutti G Tags: Aging Clin Exp Res Source Type: research

Evolution of Herpes Zoster Vaccines and Their Economic Value
Herpes zoster (HZ) affects almost 1 in 3 adults in the United States during their lifetime. The disease often causes severe pain that may last for a few weeks, with substantial influence on individuals ’ quality of life, daily activities, and work. Some patients continue to experience debilitating pain for more than a year, a complication that is known as postherpetic neuralgia (PHN). Serious cases can involve the eyes and central nervous system disease.
Source: JAMA Internal Medicine - January 2, 2018 Category: Internal Medicine Source Type: research

How Long Does Shingles Last In The Elderly?
View Original Article Here: How Long Does Shingles Last In The Elderly? Shingles is a viral infection that follows a varicella-zoster infection, although it can take decades for symptoms of the secondary disease to emerge. The condition presents as a painful and blistering rash, but it is not life-threatening. According to the Center for Disease Control, there are nearly one million cases in the United States each year, and almost half of those cases are in older adults over age 60. Some people only see one instance of the illness, while others have recurring symptoms, but 30 percent of Americans will develop shingles at s...
Source: Shield My Senior - December 8, 2017 Category: Geriatrics Authors: Vin Tags: Senior Safety Source Type: blogs